HC Wainwright Reiterates Buy Rating for Unicycive Therapeutics (NASDAQ:UNCY)

HC Wainwright restated their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY) in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a $2.50 price target on the stock.

Separately, Benchmark restated a “speculative buy” rating and set a $3.00 price target on shares of Unicycive Therapeutics in a report on Friday, September 6th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $5.13.

Unicycive Therapeutics Trading Up 2.7 %

Shares of UNCY opened at $0.46 on Tuesday. The company has a market capitalization of $43.40 million, a PE ratio of -0.47 and a beta of 2.29. Unicycive Therapeutics has a 12-month low of $0.20 and a 12-month high of $1.82. The business’s 50 day moving average is $0.43 and its 200 day moving average is $0.55.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.08. Equities research analysts predict that Unicycive Therapeutics will post -0.26 earnings per share for the current year.

Institutional Investors Weigh In On Unicycive Therapeutics

Several institutional investors have recently modified their holdings of the stock. Great Point Partners LLC purchased a new stake in Unicycive Therapeutics during the 3rd quarter valued at $3,491,000. Walleye Capital LLC bought a new position in Unicycive Therapeutics during the third quarter valued at $2,040,000. BVF Inc. IL increased its position in Unicycive Therapeutics by 70.5% during the first quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock valued at $4,984,000 after acquiring an additional 1,493,462 shares during the last quarter. Acuta Capital Partners LLC purchased a new stake in shares of Unicycive Therapeutics in the third quarter valued at $807,000. Finally, Bleakley Financial Group LLC bought a new stake in shares of Unicycive Therapeutics in the 3rd quarter worth about $33,000. 40.42% of the stock is owned by institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.